The brief · 29 April 2026

The AI brief, 2026-04-29

More voices pushing Brussels to act, an FDA testing its own medicine, and an NVIDIA model that swallows everything at once. Four stories, four different ways of taking back control over AI.

2 min read J / K to navigate

FDA Explores AI Testing for Early-Stage Clinical Trials

The FDA has opened a public consultation ahead of launching an actual pilot program. The goal: find out whether AI can speed up Phase 1 and 2 trials, the early stages where a drug is tested on a small group of patients before anyone knows if it's viable. Nothing is settled yet, but the agency is putting the question directly to industry.

practitioners › Request for Information published April 29, 2026, with responses due before an official pilot launches.

FDA →

NVIDIA drops Nemotron 3 Nano Omni, one model for text, image, video, and audio

We already covered this back on April 28 for its perception capabilities. What's new here is the format: a 30-billion-parameter hybrid MoE model with open weights, built for agentic reasoning rather than plain chat. You can download it and run it yourself.

practitioners › 30B, hybrid MoE architecture, open weights, text/image/video/audio input, released April 28, 2026.

NVIDIA →

Four US senators push to build shared AI infrastructure for research

The bill would give universities and small labs access to compute and data they can't afford on their own, currently the preserve of the big players. It won't change anything for you immediately, but it shapes who gets to build the next models you'll end up using.

practitioners › The CREATE AI Act would establish NAIRR, backed by Todd Young, Martin Heinrich, Mike Rounds and Cory Booker, reintroduced April 29, 2026.